Am J Psychiatry 159:103-108, January 2002
© 2002 American Psychiatric Association
Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Christian R. Dolder, Pharm.D.,
Jonathan P. Lacro, Pharm.D.,
Laura B. Dunn, M.D., and
Dilip V. Jeste, M.D.
OBJECTIVE: Pharmacy refill records were used to compare medication adherence in outpatient veterans receiving typical versus atypical antipsychotic medications. METHOD: Consecutive patients meeting selection criteria and receiving prescriptions for haloperidol (N=57), perphenazine (N=60), risperidone (N=80), olanzapine (N=63), and quetiapine (N=28) over a 3-month period were identified from a computerized database. The hospital policy at the time of this study required failure in trials of at least two typical antipsychotics before initiation of an atypical agent. Patients’ adherence with the antipsychotic regimen was calculated by analyzing refill records for up to 12 months. The cumulative mean gap ratio (the number of days when medication was unavailable in relation to the total number of days) and the compliant fill rate (the number of prescription fills indicating adherence in relation to the total number of prescription fills) at 6 and 12 months were calculated. RESULTS: Adherence rates at 6 and 12 months were moderately higher in patients who received atypical antipsychotics than in those who received typical agents. Cumulative mean gap ratios were 23.2% for typical and 14.1% for atypical antipsychotics at 12 months; thus, patients who received typical agents were without medication for an average of 7 days per month, compared with 4 days per month for those who received atypical agents. At 12 months, compliant fill rates were 50.1% for typical and 54.9% for atypical antipsychotics. CONCLUSIONS: Interventions to improve adherence are warranted even for patients who receive atypical antipsychotic medications.
This article has been cited by other articles:
|
|
|
|
 
L. H. Beebe, K. Smith, C. Crye, C. Addonizio, D. J. Strunk, W. Martin, and J. Poche
Telenursing Intervention Increases Psychiatric Medication Adherence in Schizophrenia Outpatients
Journal of the American Psychiatric Nurses Association,
June 1, 2008;
14(3):
217 - 224.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. I. Velligan, P. M. Diamond, J. Mintz, N. Maples, X. Li, J. Zeber, L. Ereshefsky, Y.-W. F. Lam, D. Castillo, and A. L. Miller
The Use of Individually Tailored Environmental Supports to Improve Medication Adherence and Outcomes in Schizophrenia
Schizophr Bull,
May 1, 2008;
34(3):
483 - 493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hassan, S S. Madhavan, I. D Kalsekar, E. H Makela, K. Rajagopalan, S. Islam, J. Kavookjian, and L.-A. Miller
Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder
Ann. Pharmacother.,
November 1, 2007;
41(11):
1812 - 1818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schneeweiss, S. Setoguchi, A. Brookhart, C. Dormuth, and P. S. Wang
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients
Can. Med. Assoc. J.,
February 27, 2007;
176(5):
627 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Singh, A. J. Massey, M. D. Thompson, L. R. Rappa, and M. S. Honeywell
Addressing Nonadherence in the Schizophrenic Population
Journal of Pharmacy Practice,
December 1, 2006;
19(6):
361 - 368.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Linden, T. Scheel, and F.-X. Eich
Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride
J Psychopharmacol,
November 1, 2006;
20(6):
815 - 823.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
20 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
38 - 56.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. A. Nasrallah and R. Lasser
Improving patient outcomes in schizophrenia: achieving remission.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
57 - 61.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. I. Velligan, Y.-W. F. Lam, D. C. Glahn, J. A. Barrett, N. J. Maples, L. Ereshefsky, and A. L. Miller
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature
Schizophr Bull,
October 1, 2006;
32(4):
724 - 742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Am J Psychiatry,
March 1, 2006;
163(3):
396 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Wang, S. Schneeweiss, J. Avorn, M. A. Fischer, H. Mogun, D. H. Solomon, and M. A. Brookhart
Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
N. Engl. J. Med.,
December 1, 2005;
353(22):
2335 - 2341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori, and P. M. Llorca
Direct transition to long-acting risperidone - analysis of long-term efficacy
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
15 - 21.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit, P. Braunig, and R. Medori
Long-acting risperidone in stable patients with schizoaffective disorder
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
22 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Gastpar, M. Masiak, M. A. Latif, S. Frazzingaro, R. Medori, and E. -R. Lombertie
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
32 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Landi, G. Onder, M. Cesari, C. Barillaro, A. Russo, R. Bernabei, and on Behalf of the Silver Network Home Care Study Gr
Psychotropic Medications and Risk for Falls Among Community-Dwelling Frail Older People: An Observational Study
J. Gerontol. A Biol. Sci. Med. Sci.,
May 1, 2005;
60(5):
622 - 626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Dolder, K. Furtek, J. P. Lacro, and D. V. Jeste
Antihypertensive Medication Adherence and Blood Pressure Control in Patients With Psychotic Disorders Compared to Persons Without Psychiatric Illness
Psychosomatics,
April 1, 2005;
46(2):
135 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Farabee, H. Shen, and S. Sanchez
Program-Level Predictors of Antipsychotic Medication Adherence among Parolees
Int J Offender Ther Comp Criminol,
October 1, 2004;
48(5):
561 - 571.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. P. Gilmer, C. R. Dolder, J. P. Lacro, D. P. Folsom, L. Lindamer, P. Garcia, and D. V. Jeste
Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia
Am J Psychiatry,
April 1, 2004;
161(4):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, S. Leucht, and J. M. Kane
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Am J Psychiatry,
March 1, 2004;
161(3):
414 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Kane, M. Eerdekens, J.-P. Lindenmayer, S. J. Keith, M. Lesem, and K. Karcher
Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic
Am J Psychiatry,
June 1, 2003;
160(6):
1125 - 1132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Dolder, J. P. Lacro, and D. V. Jeste
Adherence to Antipsychotic and Nonpsychiatric Medications in Middle-Aged and Older Patients With Psychotic Disorders
Psychosom Med,
January 1, 2003;
65(1):
156 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zygmunt, M. Olfson, C. A. Boyer, and D. Mechanic
Interventions to Improve Medication Adherence in Schizophrenia
Am J Psychiatry,
October 1, 2002;
159(10):
1653 - 1664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Goff
A 23-Year-Old Man With Schizophrenia
JAMA,
June 26, 2002;
287(24):
3249 - 3257.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Are Patients More Adherent on Atypical Antipsychotics than on Typical Neuroleptics?
Journal Watch Psychiatry,
February 6, 2002;
2002(206):
5 - 5.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
